These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 23918722)

  • 1. Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy.
    Hsu WW; Sing CW; He Y; Worsley AJ; Wong IC; Chan EW
    CNS Drugs; 2013 Oct; 27(10):817-27. PubMed ID: 23918722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.
    Piña-Garza JE; Rosenfeld W; Saeki K; Villanueva V; Yoshinaga H; Patten A; Williams B; Malhotra M
    Epilepsy Behav; 2020 Mar; 104(Pt A):106876. PubMed ID: 31954998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
    Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
    Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of adjunctive Perampanel in a prospective, real-world, Phase IV study in Indian patients aged ≥12 years for Treatment of focal-onset Epilepsy: Study 508.
    Ravat S; Rohatgi A; Kulkarni R; Jabeen SA; Patil B; Dash A; Malhotra M
    Epilepsia Open; 2024 Jun; 9(3):940-950. PubMed ID: 38124551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
    French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
    Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies.
    Steinhoff BJ; Patten A; Williams B; Malhotra M
    Epilepsia; 2020 Feb; 61(2):278-286. PubMed ID: 31944276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
    Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
    Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.
    Krauss GL; Serratosa JM; Villanueva V; Endziniene M; Hong Z; French J; Yang H; Squillacote D; Edwards HB; Zhu J; Laurenza A
    Neurology; 2012 May; 78(18):1408-15. PubMed ID: 22517103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
    Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
    Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
    Gidal BE; Ferry J; Majid O; Hussein Z
    Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
    Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
    Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
    Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
    Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.
    French JA; Krauss GL; Biton V; Squillacote D; Yang H; Laurenza A; Kumar D; Rogawski MA
    Neurology; 2012 Aug; 79(6):589-96. PubMed ID: 22843280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
    Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV
    Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The adverse event profile of perampanel: meta-analysis of randomized controlled trials.
    Zaccara G; Giovannelli F; Cincotta M; Verrotti A; Grillo E
    Eur J Neurol; 2013 Aug; 20(8):1204-11. PubMed ID: 23607817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of perampanel in epilepsy: A systematic review and meta-analysis of randomised controlled trials.
    Lavu A; Aboulatta L; Abou-Setta AM; Aloud B; Askin N; Rabbani R; Shouman W; Zarychanski R; Eltonsy S
    Seizure; 2022 Nov; 102():54-60. PubMed ID: 36206645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures.
    Piña-Garza JE; Lagae L; Villanueva V; Renfroe JB; Laurenza A; Williams B; Kumar D; Meador KJ
    Epilepsy Behav; 2018 Jun; 83():50-58. PubMed ID: 29653338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety.
    Lagae L; Villanueva V; Meador KJ; Bagul M; Laurenza A; Kumar D; Yang H
    Epilepsia; 2016 Jul; 57(7):1120-9. PubMed ID: 27221398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: Results of an indirect comparison meta-analysis of RCTs.
    Brigo F; Bragazzi NL; Nardone R; Trinka E
    Seizure; 2016 Nov; 42():29-37. PubMed ID: 27710868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, tolerability and safety of perampanel in population with pharmacoresistant focal seizures: A systematic review and meta-analysis.
    Mahajan SS; Prakash A; Sarma P; Niraj N; Bhattacharyya A; Medhi B
    Epilepsy Res; 2022 May; 182():106895. PubMed ID: 35305446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.